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We analyzed the medical records of patients admitted to 11 hospitals over a 15-year period,
looking for those with metabolically active sporadic pheoclhromnocytomas (Group A) and those
in whom the diagnosis was highly suspect but excluded (Group B). Fifty-three patients in
Group A and 25 patients in Group B were found. We theni devised a scoring system based on
the presence or absence of typical symptoms and signls (SSS) and anotlher whichi also included
theresults ofroutine 24-hour urine studies for catecholamines or metabolites (SSLS). Thepoint
values given for each symptom and sign were based on those felt to be most characteristic of
the disease and points were subtracted if the typical manifestation was absenit. Additionial
points were given if the symptom or sign were paroxysmal. In a highl-risk population, the semi-
sitivity of the SSS and thle SSLS was 96 percent and the specificity was 64 percenit and 88 per-
cent, respectively. The predictive value of a positive SSS was 85 percent and of a positive SSLS
was 94 percent. In a large group of patients with essential hiypertenisioni (Group C) only 17 of
385 (4.4 percent) had a positive SSS and only one of385 had a positive SSLS. We feel this scor-
ing system can help detect those hypertensive patients in whom further extensive and poten-
tially invasive evaluation is warranted.
Pheochromocytoma is perhaps the most reliably curable and dangerous cause of
secondary hypertension [1]. Although the prevalence of pheochromocytomas in
hypertensive patients is less than 0.1 percent [1,2,3], it is critically important to find
patients with this tumor. Not only can most patients be cured of their hypertension
by surgery, but also they run serious additional risks due to the metabolic and car-
diovascular consequences of catecholamine excess and the small but definite possi-
bility of malignancy [4,5].
The detection of patients with pheochromocytomas is not difficult. All cases
could presumably be found if every patient with hypertension or symptoms sug-
gestive of pheochromocytoma were screened using urine catecholamines, vanillyl-
mandelic acid (VMA), and/or metanephrines [6]. The cost and inconvenience ofthis
approach, however, would be prohibitive. Manger and Gifford calculated that
$34,000 (1977 dollars) would be spend for each patient with pheochromocytoma
found using urinary screening [1]. Since most patients with pheochromocytomas are
symptomatic, often dramatically so, we felt that we could devise a scoring system
based on the symptoms and signs commonly seen in these patients and identify the
segment of the hypertensive population most likely to have the tumor. We hoped to
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devise a system sensitive enough to include all or almost all patients with
pheochromocytomas but specific enough to reduce substantially the population at
risk for further unnecessary evaluation, and thus reduce the cost per tumor found.
The system was tested in patients with known pheochromocytomas (Group A-the
cases) and two control groups. One (control Group B) were patients admitted to the
hospital for evaluation presumably because their attending physician had a strong
clinical suspicion that they may have a pheochromocytoma. In all these patients the
tumor was excluded. A second control group were 385 consecutive unselected pa-
tients ofthe Yale-New Haven Hospital Hypertension Clinic with essential hyperten-
sion (control Group C).
METHODS
We devised a scoring system prior to chart analysis. This system assigned weighted
values to the symptoms and signs felt to occur with highest prevalence and to be
most typical of patients with pheochromocytomas (Table 1) [1]. Points were sub-
tracted from a patient's score if a characteristic manifestation of the disease was ab-
sent. The number ofpoints subtracted when a symptom or sign was missing was also
based on our estimation of the importance of that feature. Specific urinary
TABLE 1
Scoring System for Case-Finding of Pheochromocytoma
Symptoms If Present With Paroxysm Absent
Headache +6 +8 -3
Palpitations +6 +8 -4
(+ I if with chest
pain)
Sweating +5 +6 -3
Fatigue +3 - -2
Weight loss +2 --
Flushing +1 -I
Other symptoms
(including dyspnea, anxiety,
weight gain, dizziness and
syncope) + 1
Signs:
If BP is less than 140/90, -5.
If systolic BP is less than 140, diastolic BP 90-110, +5.
If systolic BP, 140-170, diastolic BP 90-110, +6.
If systolic BP is greater than 170, diastolic BP 90-110, +7.
If systolic BP is greater than 170, diastolic BP greater than 110, +8.
For documented paroxysm, add +2.
If resting pulse rate is greater than or equal to 100, +2.
If resting pulse rate is less than 100, -1.
Blood pressure in mmHg and pulse rate in beats per minute.
Urine Chemistries:
If test is not done, 0.
If test is "positive" for catecholamines, +4. If "negative," -5.
If urine was fractionated inito epinephrine and norepinephrinie, and is positive for either, +2 for each
positive value. If negative, -3.
If test is "positive" for VMA, + 1. If "negative," -2.
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measurements of catecholamines or their metabolites were the only laboratory data
used in calculation of a score for each patient.
Cases (Group A) and control Group B were found by retrieving all of the charts of
patients discharged from eleven New England hospitals from 1962-1980 for whom
the diagnosis of pheochromocytoma or "suspected pheochromocytoma" was made.
Three of these hospitals, two private and one Veterans Administration Hospital,
were major teaching hospitals, while the other eight were community hospitals af-
filiated with the Yale University School of Medicine. The charts were reviewed and
points assigned without knowledge of whether or not the patient had a pheochromo-
cytoma. The admission history and physical examination of the attending physician
and house officers was the major source of data, but we used any pertinent informa-
tion reported in the chart, either obtained prior to admission or discovered during
the hospitalization. We paid special attention to whether or not the symptoms
reported were paroxysmal. The presence or absence of each sign, symptom, and
urinary catecholamines or other metabolites was determined and summed, and each
patient was assigned a score.
The patients of the Yale-New Haven Hypertension Clinic served as an additional
control population (Group C). This was a consecutive and unselected group of pa-
tients self-referred or referred for care from several sources in the community and is
representative of the general hypertensive population. All of these patients had been
followed for at least a year when this analysis was done and have been followed for
another 36 months. None had or have developed a pheochromocytoma. Complete
data about the presence or absence of the symptoms included in the scoring system,
blood pressure and heart rate levels at referral and first visit, and urinary
catecholamine values when obtained had been previously abstracted from the pa-
tients' medical records and stored in the Yale IBM 370. Data was analyzed using
SAS, release 79.4B [7]. Each patient in this group was assigned a score, as were the
patients in Groups A and B.
Criteriafor Symptoms
Headache A characteristic headache is the most common symptom in patients
with pheochromocytoma [1]. Since headaches are so prevalent in the general popula-
tion, in Groups A and B we chose to consider only those described in the record as
throbbing and bilateral as positive. We gave six points if this symptom was present,
eight additional points if this symptom was paroxysmal, and subtracted three if this
characteristic symptom was absent. In Group C, any complaint of headache was
considered positive. Since we did not review each of these charts to obtain a descrip-
tion of the headaches, we chose to considex any notation of a headache as positive.
This may artificially increase the scores in Group C but, since a screening test should
be 100 percent sensitive and not leave out any patients who might have the disease in
question, we felt this was justified.
Palpitations Palpitations are, perhaps, the next most common symptom in pa-
tients with the tumor. Those patients who reported palpitations were given six
points, eight additional if paroxysmal, and one more if the palpitations were
associated with chest pain. Four points were subtracted if no palpitations were
reported.
Sweating Sweating is also a characteristic complaint in patients with
pheochromocytoma. Patients in whom this symptom was recorded were given five
points, six additional if paroxysmal, and three points were subtracted if the symp-
tom was not mentioned in the medical record.
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Other Symptoms Several other symptoms are commonly reported in patients
with pheochromocytoma but are not seen as often as headache, palpitations, or
sweating. These include fatigue, weight loss of greater than ten pounds since the
onset of hypertension, and flushing. These and other less common and more non-
specific symptoms were also looked for and assigned what we felt were more ap-
propriate point values. (Refer to Table 1.)
Criteriafor Signs
Hypertension An elevated blood pressure is, ofcourse, the most common sign in
patients with this tumor. We chose to use the highest blood pressure noted or re-
corded in the medical record, whether or not that reading represented a value actu-
ally obtained on that admission. Patients were defined as having paroxysmal
hypertension if we could document a sudden change or at least 30 mmHg systolic
and 15 mmHg diastolic on at least two or more occasions not associated with anti-
hypertensive therapy. (Refer to Table 1 for point values.)
Orthostatic hypotension is often described as being a characteristic feature in pa-
tients with pheochromocytoma. In our study, however, we could not use this finding
since postural changes in blood pressure were rarely recorded.
Tachycardia We considered resting pulse rates only and those which were not af-
fected by therapy (Table 1). Standing pulse rates may exceed 100 beats per minute
for many reasons and so are not specific enough to be useful. As with blood pres-
sure, data on the change in pulse rating with sitting or standing was not complete
enough to be used for the scoring system.
OtherSigns We neither added nor subtracted for other physical signs commonly
reported such as hyperhidrosis, severe retinopathy, fever, or abdominal masses.
Criteriafor Laboratory Values
Urinary Catecholamines and Their Metabolites Total urinary catecholamines
were used as a screening test in most of those patients in Groups A and B although
several only had VMA studies. We recorded the actual level of the highest reported
sample when available. In a few patients, urinary samples were fractionated into
norepinephrine and epinephrine. We considered the value as "normal" or "abnor-
mal" according to the norms for each hospital. Point values were assigned if the
levels were abnormal and subtracted if not, whatever the absolute level (Table 1).
OtherLaboratory Tests Although some routine laboratory values such as serum
glucose and hematocrit are often abnormal in patients with pheochromocytoma, we
felt these tests were too nonspecific to warrent being included in our point score. No
patients in this group had plasma catecholamines measured as a screening test. In all
instances, radiological procedures were undertaken after the diagnosis of pheo-
chromocytoma was already suspected.
Criteriafor Diagnosis
Pheochromocytoma Present (Group A) All patients classified as having a
pheochromocytoma had a surgical or postmortem specimen considered consistent
with this diagnosis by the attending pathologist at the respective institution. In no
patients in this group was there any doubt expressed about the proper histologic
diagnosis.
Pheochromocytoma Absent (Group B) All of these patients had negative
arteriograms and no evidence of pheochromocytoma after at least eighteen months
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follow-up. This was either documented later in the medical record or, in four in-
stances, by direct contact with the attending physician. No patients were directly
contacted. In one patient (number 61), the clinical suspicion ofpheochromocytoma
was so high that she underwent bilateral adrenal vein catheterization and eventual
unilateral adrenalectomy but no tumor was found. Any patients whose adequate
diagnostic or follow-up information was incomplete was excluded from the study.
We arbitrarily defined 9 as a positive symptom and sign score (SSS), and 13 as
positive when laboratory work, urinary catecholamine, or metabolite studies were
included (symptom, sign, and laboratory score-SSLS).
RESULTS
Sixty patients with proven pheochromocytomas were found (Table 2). Fifty-four
were patients with sporadic pheochromocytomas and six were patients with multiple
endocrine adenomatosis (MEA), Type 2. Since the pheochromocytomas in several
patients with MEA, Type 2, were discovered because of their family history rather
than their symptoms, we have chosen not to include them in any further analysis.
Similarly, we have excluded the one asymptomatic, normotensive patient whose
tumor was found at autopsy and probably was metabolically inactive. The remain-
ing 53 patients constitute Group A. Two of these tumors (3.3 percent) were malig-
nant and four patients had died (one post-operatively of shock, the case discovered
incidentally at autopsy, and the two with malignancies). Twenty-five patients in
Group B were found.
Of the patients with metabolically active sporadic pheochromocytomas (Group
A), 51 had a symptom and sign score (SSS) of nine or more and 50 of the 53 had a
symptom, sign, and laboratory score (SSLS) of 13 or more. In Group B (Table 3) 9
patients had an SSS of 9 or more, but only 3 had an SSLS of 13 or more. These
results are graphically represented in Fig. 1. The symptoms and signs found in the
patients of Groups A and B are shown in Table 4.
Of the 385 patients in Group C, only 17 (4.4 percent) had an SSS of 9 or more,
thereby suggesting that screening urine studies were indicated. In these 17 patients,
urinary studies had been obtained in 14 and all were normal. Adequate follow-up
data eventually confirmed that none of these patients had a pheochromocytoma.
Only one of these patients had an SSLS of 13 or more. No further diagnostic pro-
cedures have been done, and the patient is well with no evidence of a pheochromo-
cytoma after more than three years of follow-up.
Treating the SSS and SSLS as if they were laboratory tests, we calculated the sen-
sitivity, specificity, accuracy of a positive prediction (predictive value) and the ac-
curacy of a negative prediction (exclusion value) as recommended by Ransohoffand
Feinstein [8].
We first performed these calculations for the high-risk patients (Groups A and B)
(Table 5). Then, in order to get a better idea of the value of this scoring system in a
more general population, we recalculated the data for Groups A, B, and C com-
bined (Table 6). Since three of the patients in Group C did not have urinary cate-
cholamines obtained, we assumed, for the sake of the analysis, that these had been
done and were positive.
The sensitivity, specificity, predictive value, and exclusion value are listed in Table
5 for high-risk patients (Groups A and B) and in Table 6 for our estimate of the
more general population (Groups A, B, and C).
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SYMPTOMS AND SIGNS SCORE
(SSS)
SYMPTOMS, SIGNS,
AND LABORATORY SCORE
(SSLS)
PRESENT EXCLUDED
E
PRESENT EXCLUDED
PHEOCHROMOCYTOMA
FIG. 1. Left-hand column shows SSS and
right-hand column SSLS. Patients with
pheochromocytoma (Group A) are dis-
played with closed circles and those with
diagnosis excluded (Group B) with open
circles.
TABLE 4
Symptoms in Patients with Metabolically Active Sporadic Pheochromocytoma (Group A)
Percentage of total patients
Symptom (N = 53) Paroxysmal
Headache 96 70
Excess sweating 74 64
Palpitations 70 64
Chest and epigastric pain 50 48
Anxiety, dread 46
Fatigue, weakness 40
Weight loss (> 10 pounds) 25
Dyspnea 10
Flushing 8
Nausea with and without
vomiting 10
Symptoms in Patients without Pheochromocytoma (Group B)
Percentage of total patients
Symptom (N = 25) Paroxysmal
Headache 67 12
Excess sweating 37.5 8
Palpitations 29 5
Fatigue, weakness 33
Anxiety, dread 29
Weight loss 8
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TABLE 5
High-Risk Patients-Groups A + B
sss
Pheochromocytoma P
Yes (+) No (-)1
51 9 (>12)
SSLS
-
2 16 (<12) L
Sensitivity
Specificity
Accuracy of positive prediction
(predictive value)
Accuracy of negative prediction
(exclusion value)
sss
51 -6
53
25
51
0--85%
16
18-88%
SSLS
'heochromocytoma
Yes (+) No (-)
51 3
2 22
SSLS
51
53-96%
22
2-5-88%
51
-4-94%
22
-4-92%
TABLE 6
More General Hypertension Population
(Groups A, B, and C)
(>8)
SSS
(< 8)
sss
Pheochromocytoma
Yes (+) No (-)
51 26
2 384
Sensitivity
Specificity
Accuracy of positive prediction
(predictive value)
Accuracy of negative prediction
(exclusion value)
SSLS
Pheochromocytoma
Yes (+) No (-)
(>12) 51 4
SSLS
(<12) 2 406
SSS SSLS
96% 96% 53 53
384_94% 406_99%
410 410
51 _6%51 _3 -660o 5-93%7
77 55
384 -9.% 0_99.5%
386 408
268
(>8)
ssS
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DISCUSSION
The conscientious and thorough physician who is also cost-conscious has a serious
dilemma when evaluating patients with hypertension. Curable secondary causes of
hypertension are very rare, but usually there are clinical or laboratory clues which
help raise the physician's index of suspicion and guide him or her to the right
diagnosis. For primary aldosteronism, serum K' is almost always abnormal, and this
inexpensive non-invasive test is an excellent case-finding tool to discover patients
with this disease. Patients with renovascular hypertension will often have abdominal
bruits, and Grim and colleagues have recently shown that the presence of this
physical finding is as good as any laboratory or radiological test in finding patients
with this condition [9]. The patient with a pheochromocytoma, on the other hand,
can be very difficult to diagnose, and there is a strong possibility of a rapidly lethal
outcome, if the tumor is missed or the patient mismanaged. Fortunately, a reli-
able case-finding test exists for this tumor, namely, timed urine collections for
catecholamines or metabolites. Unfortunately, as Manger and others have pointed
out [1,10,11], the cost of screening all hypertensive patients to find the one in a thou-
sand with the tumor would be financially prohibitive [1].
Most patients with pheochromocytomas are symptomatic, often in a character-
istic way. We felt that a clinical scoring system, based on a properly weighted score,
could first help us select those patients in whom urine studies should be done and
then, second, when those results were available, predict which patients were most
likely to have the tumor, and thus warrant more invasive and dangerous studies.
The choice of which symptoms and signs to include in the system was based on
those reported most commonly to occur in patients with pheochromocytomas. We
gave special weight to the paroxysmal nature of the symptoms and blood pressure,
not only because these are often seen in patients with pheochromocytomas, but
because such "attacks" are relatively unusual in patients with other causes for
hypertension, even if they have many of the characteristic complaints. We hoped to
improve the sensitivity and specificity of the system by subtracting points when
typical symptoms or signs were not present and when urine studies were not
elevated. Since we felt that our results could be seriously biased if the chart reviewer
(SB) knew whether the patient did or did not have a pheochromocytoma when he
abstracted the medical record, all records were requested at the same time and the
scores assigned before he knew if the patient had a tumor. The way the system was
designed, most of the data which required subjective assessment was obtained from
the initial history and physical examination and most, if not all, these patients would
not have had a definite diagnosis made until considerably later in their hospitaliza-
tion.
Our series of cases is reasonably large, but the fact that we could only find 60 pa-
tients in an eighteen-year period in eleven hospitals emphasizes the rarity of this con-
dition. We feel that we have included all patients with the disease who were admitted
during this time period and that there were no other evident sources of bias in the
assignment of the scores.
Patients with tumors associated with familial conditions are different. They are
often discovered before symptoms occur. Once a member or members of their fam-
ily are found to have a medullary carcinoma of the thyroid or other features of the
MEA type 2 syndrome, medical surveillance increases and asymptomatic disease is
found. Thus, we did not include this group in our analysis.
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Our scoring system appears a very valuable tool. It uses only data obtained from a
careful history and physical examination and non-invasive and inexpensive
laboratory tests and adds neither risk nor cost to the evaluation of patients likely to
have a pheochromocytoma. We have chosen to both add and subtract points in an
attempt to make this system a more powerful discriminator. When studying a
disease with such a characteristic clinical presentation, the absence of a typical
symptom is just as important as its presence and so we chose to take points away if
the finding was not in evidence. Others have also subtracted points when using
clinical information to generate a score to assist in clinical decision making [12]. The
symptom and sign score is sensitive enough (96 percent) to select those patients who
should undergo the expense and inconvenience of collecting a 24-hour urine with the
assurance that few patients with the disease will be missed. In fact, this sensitivity is
comparable to that reported in the literature for arteriography (83 percent) [13] and
the 87 percent sensitivity (46 of 53) arteriography had in Group A in our series. The
specificity in an unselected group of hypertensive patients, none of whom had the
disease, was 95.6 percent. So in only 4.4 percent of the hypertensive population
would it be necessary to collect urinary studies, and only one of 385 patients had a
high enough SSLS to warrant further work-up to exclude a pheochromocytoma.
Even in the patients whose history and physical examination suggested they had a
pheochromocytoma (Group B), only 9 of 25 (36 percent) would have had urine
studies done and only 3 of 25 (12 percent) would have been evaluated with invasive
and expensive procedures, which had been done in all of those patients.
The ability of any diagnostic test or scoring system to find cases of a rare disease
in a large population is limited. If there are any false-positive tests, the predictive
value of a positive test becomes small, and the test loses its utility. The value of any
test can be increased, if the prevalence of the disease can be increased by more
carefully defining the population in whom the test should be done. Since we did not
screen an unselected group of patients to find our cases, we do not really know how
valuable our scoring systems would be in the general hypertensive population. We
attempted to overcome this shortcoming in two ways. First, since we feel that we
have included all cases admitted to these eleven hospitals during the years of the
study, we feel we can accurately calculate the accuracy of a positive or negative
prediction of the SSS or SSLS and in high-risk populations (Groups A and B). For
both scores, the accuracy in these groups is quite good (Table 5). By adding in the
patients from a large unselected population from the Yale Hypertensive Clinic
(Group C), we tried to estimate more correctly the predictive and exclusion values of
the scoring systems in a general hypertensive population. The values of 66.1 percent
and 99.4 percent for SSS and 93 percent and 99.5 percent for SSLS appear to make
the tests valuable, but the prevalence of pheochromocytoma in these undetermined
populations is inordinately high (11 percent, 53/463) and may not offer an estimate
of the value of the test. By using it, however, we are able to pick out the 4.4 percent
of the patients most likely to need urine studies and the one in 385 in whom invasive
work-up might have been indicated.
Recently, a group of French workers have published a study similar to ours. They
questioned 2,585 unselected hypertensive patients, looking for those with attacks of
headaches, palpitations, and sweating [14]. In their series, only 6.5 percent had all
three symptoms and 10 ofthe 11 patients with pheochromocytomas were included in
that group. The sensitivity (93.8 percent), specificity (90.8 percent), and exclusion
value (99.9 percent) appear quite good. But the predictive accuracy was only 5.9 per-
cent (10/170) in their high-risk population (those with all three symptoms), com-
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pared to 85 percent using the SSS in Groups A and B in our study. Thus we feel the
additional data obtained to generate our SSS and SSLS contribute significantly to
the value of this approach.
Many new laboratory techniques to diagnose pheochromocytomas have been pro-
posed. None of our patients, for example, had plasma catecholamines measured.
Several authors have recently suggested that measuring these levels may be very
helpful in screening hypertensive patients for pheochromocytomas [15,16]. It is our
feeling that the conditions under which these studies should be performed are still
unclear, that the methodology is difficult to perform properly in routine labora-
tories, and that the cost would be prohibitive if these measurements were done in
the general hypertensive population. Abdominal computerized axial tomography
has recently become a valuable adjunct to the radiologic methods used to locate
pheochromocytomas [17]. The sensitivity ofthis test is excellent (91 percent), but the
expense and the risk of contrast-induced catecholamine crisis is too high to expect
that this test will be useful as a case-finding tool in unselected hypertensive patients.
The utility of other new methods such as 131I meta-iodobenzylguanidine scanning
[18] or measurements of platelet catecholamine concentrations [19] are still uncer-
tain. All of these techniques may make positive diagnosis more rapid and certain,
but clinical tools will still be needed to select properly those patients in whom the
tests should be performed.
We feel that our scoring system properly quantifies the signs and symptoms in pa-
tients with pheochromocytoma so that the clinicians can applycase-finding techniques
in a population where the prevalence ofthis rare disease has been significantly aug-
mented. Should this prediction prove valid, then historical data and careful blood
pressure and pulse measurements will cheaply and accurately find the patients at
risk of this lethal tumor without spending our limited resources needlessly. We
would hope that when the clinician suspects that his or her patients might have a
pheochromocytoma, he or she will use Table 1 to determine SSS and to decide
whether it's worth spending money on urinary catecholamines or metabolites. If so,
once these studies have been done, then he or she can then determine the SSLS and
decide whether to proceed on to more expensive, invasive, and dangerous pro-
cedures. Whether or not this scoring system will be discriminating enough to quan-
tify clinical judgment cannot be determined from this retrospective analysis. Only
its use in a prospective fashion in large groups of hypertensive patients can answer
that question.
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